Results 1 to 10 of about 17,343 (263)

Epigenomic response to albuterol treatment in asthma-relevant airway epithelial cells

Clinical Epigenetics, 2023
Background Albuterol is the first-line asthma medication used in diverse populations. Although DNA methylation (DNAm) is an epigenetic mechanism involved in asthma and bronchodilator drug response (BDR), no study has assessed whether albuterol could ...
Javier Perez-Garcia, Maria Pino-Yanes, Elizabeth G. Plender, Jamie L. Everman, Celeste Eng, Nathan D. Jackson, Camille M. Moore, Kenneth B. Beckman, Vivian Medina, Sunita Sharma, Daniel Efrain Winnica, Fernando Holguin, José Rodríguez-Santana, Jesús Villar, Elad Ziv, Max A. Seibold, Esteban G. Burchard   +16 more
doaj   +2 more sources

Optimization of Albuterol Delivery via Anesthesia Bag in Pediatric Critical Care. [PDF]

Pharmaceutics
Background/Objectives: Aerosolized medications are common practice for mechanically ventilated pediatric patients. Infants often receive nebulized medications via hand ventilation using an anesthesia bag, but evidence on optimal aerosol delivery with ...
Tessier S, Ploszay VK, Robitaille C, Vaghasiya J, Halayko AJ, Chartrand L.   +5 more
europepmc   +2 more sources

Albuterol, Acidosis, and Aneurysms [PDF]

Federal Practitioner, 2021
A patient with a complicated medical history on admission for dyspnea was administered nebulizer therapy but after 72 hours developed asymptomatic acute kidney injury and anion-gap metabolic acidosis.
Lucy Ma, Raj Singaraju, Christopher Russo   +2 more
openaire   +3 more sources

Dexmedetomidine as an adjunctive treatment for acute asthma [PDF]

Clinical and Experimental Emergency Medicine, 2021
Objective This study aimed to compare the efficacy of using dexmedetomidine with salbutamol and salbutamol nebulization alone in patients with acute exacerbation of asthma presenting to the emergency department.
Hassan Motamed, Arash Forouzan, Meisam Moezzi, Hossein Alizadeh   +3 more
doaj   +1 more source

Association between dispensing of low-value oral albuterol and removal from Medicaid preferred drug lists

BMC Health Services Research, 2022
Background Oral albuterol has worse efficacy and side effects compared with inhaled albuterol, and thus its use has been discouraged for decades. Drug inclusion or exclusion on formularies have been associated with reductions in low-value care.
Anna Volerman, Alison Pelczar, Rena Conti, Christina Ciaccio, Kao-Ping Chua   +4 more
doaj   +1 more source

β2-Agonists inhibit TNF-α-induced ICAM-1 expression in human airway parasympathetic neurons. [PDF]

PLoS ONE, 2012
Major basic protein released from eosinophils to airway parasympathetic nerves blocks inhibitory M(2) muscarinic receptors on the parasympathetic nerves, increasing acetylcholine release and potentiating reflex bronchoconstriction.
Zhenying Nie, Allison D Fryer, David B Jacoby   +2 more
doaj   +1 more source

Preferential Pulmonary Retention of (S)-Albuterol after Inhalation of Racemic Albuterol [PDF]

American Journal of Respiratory and Critical Care Medicine, 1999
The (R)-enantiomer of racemic albuterol produces bronchodilation, whereas the (S)-enantiomer may increase airway reactivity. After oral or intravenous administration of racemic albuterol, the (R)- enantiomer is metabolized several times faster than the (S)-enantiomer; however, enantiomer disposition after inhaling racemic albuterol with a metered-dose ...
Mark L. Goode, James B Fink, Ralston W. Reid, Patrick J. Fahey, Rajiv Dhand, Martin J. Tobin   +5 more
openaire   +3 more sources

Nebulized albuterol delivery is associated with decreased skeletal muscle strength in comparison with metered‐dose inhaler delivery among children with acute asthma exacerbations

Journal of the American College of Emergency Physicians Open, 2021
Objective Albuterol is a β2‐agonist and causes an intracellular shift of potassium from the interstitium. Whole‐body hypokalemia is known to cause skeletal muscle weakness, but whether this occurs as a result of hypokalemia from the intracellular shift ...
Catherine Burger, Danica F. Vendiola, Donald H. Arnold   +2 more
doaj   +1 more source

Effects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis. [PDF]

PLoS ONE, 2014
The β2-adrenergic receptor agonist, albuterol, has been reported beneficial in treating several forms of congenital myasthenia. Here, for the first time, we examined the potential benefit of albuterol in a mouse model of anti-Muscle Specific Kinase (MuSK)
Nazanin Ghazanfari, Marco Morsch, Nigel Tse, Stephen W Reddel, William D Phillips   +4 more
doaj   +1 more source

Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence [PDF]

Sci Rep 11, 23179 (2021), 2020
Amid the pandemic of 2019 novel coronavirus disease (COVID-19) infected by SARS-CoV-2, a vast amount of drug research for prevention and treatment has been quickly conducted, but these efforts have been unsuccessful thus far. Our objective is to prioritize repurposable drugs using a drug repurposing pipeline that systematically integrates multiple SARS-
arxiv   +1 more source